AIM AIM ImmunoTech

$AIM Back in with only a small position. This patent is worth billions. The ability to amplify the effects of checkpoint inhibitors (and other oncologic agents) by triggering both CD4 and CD8 via TLR3 agonism and turning cold into hot tumors, is one of the holy Grail‘s in cancer treatment. I remain nearly 100% however in $SLS as it is way closer to ripening. $AIM could get a buyout, however at any moment – – just much more of a lotto ticket. Will load here heavily again once SLS launches.

$AIM its merk naked shorting lol. They mad because they wanted ampligen for themselves and tried to screw over aim. Now that aim has the patent they are pissed. If they want ampligen now no copy bs they have to pay billions.

$AIM People trying go keep it down..playing with fire. The borrow rate increased 4 times today from past 1 week. $VIVK $ANNA $GPRO

$AIM if you could do me a favor please ignore from the negativity people in every tweet section of every stock you have a couple of people that like to put negative news or box that do that or just short sellers try to change and manipulate your opinion the market today heavily control by manipulation in short sellers unfortunately this thing will fly and I'm not even sure which price we can get to be honest I truly believe it could go above 0.5

$AIM The Numbers are as good as the management is bad. 21% complete response is crazy! Do you even know what that means?

$AIM Not selling below $1. it has already done it twice from these levels without back to back news like this week. Dont fall in same the trap of - "The moment I sell the stock rises". Let it rise. And rise good. Do you other job. Set a high limit and forget short term.

$AIM $AIM Huge Catalyst! 🚨 Just secured a major U.S. patent through 2039 for combining Ampligen with Merck's Keytruda (pembrolizumab) across major cancers like pancreatic and lung cancer! Micro-cap stock heavily oversold at ~$0.23—this kind of long-term IP protection combined with a low float can easily trigger a massive 1000%+ squeeze once clinical momentum builds. Massive upside potential at these levels! 📈🚀

$AIM If you had a 400k promissory note would you accept shares in exchange? Think it settles the so called imminent reverse split possibility a more unlikely outcome! Not saying never but this confidence is at least more optimistic for the immediate future.

$AIM why does Equels insist on representing the science himself. He has no more credibility in my book. I want to hear from the doctors and scientists. Not a lawyer that should have retired years ago. The pattern.. he speaks, stock tanks.

$AIM I hope this gives some relief. No scam. Legit partnerships. Recent Buybacks. Patent till 2039. No eyes on it yet. Stop chasing scams. $PPBT

$AIM Equels acquired 22,000 shares at $0.221 for a total of $4,862. He probably pays more than that per week to feed and care for his horses. Buying such a piddling amount is akin to damning with faint praise.

$AIM 👯‍♀️ more patent news hit, volume picking up, trail stop just flipped bullish with massive upside potential 💨

$AIM For newbies:  Ampligen, or rintatolimod, is a synthetic mismatched double-stranded RNA that acts as a selective TLR3 agonist. It binds endosomal TLR3 and signals mainly through the TRIF pathway. That triggers type I interferons, activates natural killer cells, matures dendritic cells, and boosts cytotoxic T-cell activity. In tumors it selectively pulls in killer T cells while reducing regulatory T-cell attraction, which can convert cold tumors into hotter ones more responsive to checkpoint inhibitors. It also shows direct antiproliferative effects on some cancer cells that express TLR3.

$AIM Efficacy data is already out and looks strong on its face (a 50% ORR in platinum-sensitive recurrent ovarian cancer. What’s still pending: secondary endpoints — progression-free survival, time to disease progression, and additional overall survival data — with collection expected to be completed in January 2027, per AIM’s most recent 10-Q. News to watch is a expanded collaboration with Merck which will happen especially with Merck patent expiration coming up in 28 they are desperate to find the next big thing.

$AIM I only give my analysis and personal recommendation I do not try to manipulate people opinion or change their decision or behavior the fact is that I did alert about this stock the moment I knew she's going to explode from 0.22 and we are only starting and I know when somebody write me a disrespectful message he has an agenda anyway she has big news and the value of the company changing because upward 👆🏼⬆️

$AIM with the ebola outbreak seems to be 0 shares availability for shorting ~ 🍋💦 squeeze time ⏲️

$AIM AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041

$AIM either the ATM was turned on or shorts attacked viciously but either way this has reversed 58% today. Penny stocks are insane. Holding 20,000 for the bump up

$AIM AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039

$AIM Current Status & Strategy Active Pursuit: AIM is actively positioning Ampligen as a broad-spectrum antiviral countermeasure to secure non-dilutive grants, contracts, or partnership funding from federal agencies such as the Department of Defense (DoD) or BARDA. Capital Allocation Priority: AIM’s core R&D budget remains focused on its pancreatic cancer Phase 3 clinical pipeline. The company has stated it will only advance human clinical trials for Ebola or biodefense if non-dilutive government backing or external grant funding is secured. Recent Catalysts & PR Push May/June 2026: Following a World Health Organization (WHO) emergency declaration over the Bundibugyo Ebola outbreak in East Africa, AIM launched an investor and biodefense campaign highlighting USAMRIID BSL-4 preclinical mouse data (100% survival rate).